Search

everythinglearnresearchcommunity

for

Search:↓

Children's hair loss can be caused by various factors and should be treated with appropriate, age-specific methods and psychological support.

Chlormadinone acetate is a strong, well-tolerated hormone used in birth control and hormone therapy with benefits for menstrual pain and skin conditions.

Young women with PCOS have a higher risk of high blood pressure and metabolic syndrome, but these risks may decrease after age 40.

South Asian women with PCOS present with different symptoms compared to White women, influenced by ethnicity, obesity, and age.

Many infertile women with PCOS in Central Vietnam have metabolic or insulin resistance syndrome, with obesity and older age increasing the risk.

Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.

Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.

Cinnamon can help manage symptoms of polycystic ovary syndrome, improve menstrual cycles and fertility, and positively affect cholesterol and blood sugar levels, but more research is needed to confirm these effects and find the best dosage.

PCOS starts in adolescence with hormonal issues, leading to adult health problems, and early treatment is crucial.

The document concludes that various drugs can manage symptoms and metabolic issues in women with PCOS.

Acne is strongly linked to high BMI, hair loss, menstrual issues, family history, and eating too many sweets and fatty foods, but not to excessive hair growth.

Isoflavone may help manage PCOS symptoms, but its effectiveness is uncertain.

Ayurvedic treatment helped a woman with PCOS conceive and deliver a healthy baby.

Women with acne after adolescence are more likely to have PCOS and should be checked for it.

Treating ovarian-related inflammation may help hair regrowth in women with alopecia areata.

PCOS is a complex condition with major health impacts, needing more research for better diagnosis and treatment.

Most women with excess male hormones have Polycystic Ovary Syndrome, and hormonal therapy can improve symptoms but may cause side effects.

Early detection and intensive treatment of diseases caused by Staphylococcus aureus toxins are crucial for reducing severe health effects.

The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.

Spironolactone effectively reduces hair growth in women with hirsutism and is generally well-tolerated.

Metformin and rosiglitazone improve blood vessel function in women with PCOS, with metformin also reducing insulin resistance and testosterone levels.

The document concludes that treating PCOS requires a combination of drugs to manage reproductive and metabolic symptoms, with more research needed on combination therapies.

Diagnosing PCOS in teenagers is hard because its symptoms often look like normal puberty, and there's a need for better diagnosis methods and agreement on criteria.

Diagnosing PCOS in teenagers should focus on signs of excess male hormones and not rely solely on ovarian ultrasound or irregular periods, and should be reassessed in adulthood.

Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.

The combination therapy improved PCOS symptoms in both obese and non-obese women, with weight loss in the obese group.

Most cases of excessive hair growth in women are caused by polycystic ovarian syndrome and are linked to higher free testosterone levels.

Primary care for PCOS focuses on lifestyle changes, medication based on symptoms, and mental health, with diabetes screening and specialist referral for severe cases.

Alfacalcidiol and metformin together lowered testosterone in women with PCOS, but did not significantly improve acne, hair growth, or pregnancy rates.

The severity of symptoms in nonclassical congenital adrenal hyperplasia is not determined by CYP21A2 gene variations.